---
title: "Lysergide (DT120) in Generalized anxiety disorder: Buspirone"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Buspirone. Topics: FDA-approved indication and duration of demonstrated efficacy, Adverse events and discontinuation in premarketing trials, Abuse and dependence potential, CANMAT guideline: second-line agent, and 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/buspirone"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Buspirone

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Buspirone

<a id="topic-2.2.2.1.5-1"></a>

### FDA-approved indication and duration of demonstrated efficacy

> “BuSpar is indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.”
> “The efficacy of BuSpar has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD).”
> “The effectiveness of BuSpar in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials.”

Source: [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### Adverse events and discontinuation in premarketing trials

> “The more commonly observed untoward events associated with the use of BuSpar not seen at an equivalent incidence among placebo-treated patients include dizziness, nausea, headache, nervousness, lightheadedness, and excitement.”
> “Approximately 10% of the 2200 anxious patients who participated in the BuSpar premarketing clinical efficacy trials in anxiety disorders lasting 3 to 4 weeks discontinued treatment due to an adverse event.”

Source: [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Abuse and dependence potential

> “BuSpar (buspirone hydrochloride) is not a controlled substance.”
> “In human and animal studies, buspirone has shown no potential for abuse or diversion and there is no evidence that it causes tolerance, or either physical or psychological dependence.”

Source: [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

### CANMAT guideline: second-line agent

> “Buspirone was more effective than placebo and as effective as benzodiazepines in several RCTs (Level 1)”
> “Limited effectiveness in clinical practice relegates buspirone to a second-line agent.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.5-5"></a>

### BAP guideline: acute efficacy without relapse-prevention evidence

> “The azapirone drug buspirone is efficacious in the acute treatment of generalised anxiety disorder”
> “though neither has published evidence of efficacy in the prevention of relapse.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.5-6"></a>

### Cochrane review of azapirones

> “Thirty six trials were included in the review, reporting on 5908 participants randomly allocated to azapirones and/or placebo, benzodiazepines, antidepressants, psychotherapy or kava kava. Azapirones, including buspirone, were superior to placebo in treating GAD. The calculated number needed to treat for azapirones using the Clinical Global Impression scale was 4.4 (95% confidence interval (CI) 2.16 to 15.4). Azapirones may be less effective than benzodiazepines and we were unable to conclude if azapirones were superior to antidepressants, kava kava or psychotherapy. Azapirones appeared to be well tolerated. Fewer participants stopped taking benzodiazepines compared to azapirones. The length of studies ranged from four to nine weeks, with one study lasting 14 weeks.”
> “Longer term studies are needed to show that azapirones are effective in treating GAD, which is a chronic long‐term illness.”

Source: [Chessick et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8915394/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
